TY  - GEN
AU  - Cayuela,Jean-Michel
AU  - Chomel,Jean-Claude
AU  - Coiteux,Valérie
AU  - Dulucq,Stéphanie
AU  - Escoffre-Barbe,Martine
AU  - Etancelin,Pascaline
AU  - Etienne,Gabriel
AU  - Hayette,Sandrine
AU  - Millot,Frédéric
AU  - Nibourel,Olivier
AU  - Nicolini,Franck-Emmanuel
AU  - Réa,Delphine
TI  - [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia]
SN  - 1769-6917
PY  - 2020///0227
KW  - Antineoplastic Agents
KW  - therapeutic use
KW  - Catalytic Domain
KW  - Clinical Decision-Making
KW  - DNA Mutational Analysis
KW  - methods
KW  - DNA, Neoplasm
KW  - analysis
KW  - Drug Resistance, Neoplasm
KW  - genetics
KW  - Drug Substitution
KW  - Fusion Proteins, bcr-abl
KW  - antagonists & inhibitors
KW  - High-Throughput Nucleotide Sequencing
KW  - Humans
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - drug therapy
KW  - Molecular Biology
KW  - Mutation, Missense
KW  - Point Mutation
KW  - Protein Domains
KW  - Protein Kinase Inhibitors
KW  - Role
N1  - Publication Type: Consensus Development Conference; Journal Article; Practice Guideline; Review
UR  - https://doi.org/10.1016/j.bulcan.2019.05.011
ER  -